humatrope 12 mg prašek in vehikel za raztopino za injiciranje
eli lilly farmacevtska druŽba, d.o.o. - somatropin, rekombinantni - prašek in vehikel za raztopino za injiciranje - somatropin, rekombinantni 12 mg / 1 vložek - somatropin
humatrope 6 mg prašek in vehikel za raztopino za injiciranje
eli lilly farmacevtska druŽba, d.o.o. - vehikel - prašek in vehikel za raztopino za injiciranje - vehikel 3,17 ml / 1 vložek - somatropin
humatrope 24 mg prašek in vehikel za raztopino za injiciranje
eli lilly farmacevtska druŽba, d.o.o. - somatropin, rekombinantni - prašek in vehikel za raztopino za injiciranje - somatropin, rekombinantni 24 mg / 1 vložek - somatropin
waylivra
akcea therapeutics ireland limited - volanesorsen natrijev - hiperlipoproteinemija tipa i - drugih lipidov spreminjanje agenti - waylivra je indicirano kot dodatek k dieti pri odraslih bolnikih z gensko potrdili družinsko chylomicronemia sindrom (fcs) in na visoko tveganje za pankreatitisa, v kateri je odziv na dieto in trigliceridov znižanje terapija je bila neustrezna.
pemetreksed sandoz 25 mg/ml koncentrat za raztopino za infundiranje
pemetreksed - koncentrat za raztopino za infundiranje - pemetreksed 25 mg / 1 ml - pemetreksed
pemetreksed sandoz 25 mg/ml koncentrat za raztopino za infundiranje
pemetreksed - koncentrat za raztopino za infundiranje - pemetreksed 25 mg / 1 ml - pemetreksed
pemetreksed sandoz 25 mg/ml koncentrat za raztopino za infundiranje
pemetreksed - koncentrat za raztopino za infundiranje - pemetreksed 25 mg / 1 ml - pemetreksed
tyruko
sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresivi - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 in 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.
pemetreksed teva 500 mg prašek za koncentrat za raztopino za infundiranje
teva b.v. - pemetreksed - prašek za koncentrat za raztopino za infundiranje - pemetreksed 500 mg / 1 viala - pemetreksed
pemetreksed teva 1000 mg prašek za koncentrat za raztopino za infundiranje
teva b.v. - pemetreksed - prašek za koncentrat za raztopino za infundiranje - pemetreksed 1000 mg / 1 viala - pemetreksed